XENE
NASDAQXenon Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks52-62%
2025-10-262026-04-19
Mix2990d
- SEC Filings13(45%)
- Insider6(21%)
- Other4(14%)
- Offering3(10%)
- Earnings2(7%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Xenon Pharmaceuticals Inc.DEFA14A - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form DEF 14A filed by Xenon Pharmaceuticals Inc.DEF 14A - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon to Present at Upcoming Investor ConferencesVANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026. Bloom Burton & Co. Healthcare Investor Conference, Toronto, OntarioCompany Presentation: Wednesday, April 22, 2026, 11:30 am–12:00 pm ETBank of America Global Healthcare Conference, Las Vegas, NVCompany Presentation: Thursday, May 14, 2026, 8:00–8:30 am PT (11:00–11:30 am ET)RBC Capital
- SECSEC Form S-8 filed by Xenon Pharmaceuticals Inc.S-8 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingFive abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announc
- INSIDERChief Medical Officer Kenney Christopher John converted options into 3,750 shares and sold $77,867 worth of shares (1,410 units at $55.23), increasing direct ownership by 49% to 7,069 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERChief Legal Officer Difabio Andrea sold $74,112 worth of shares (1,342 units at $55.22) and converted options into 3,750 shares, increasing direct ownership by 49% to 7,301 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERPRESIDENT & CEO Mortimer Ian converted options into 12,500 shares and sold $403,584 worth of shares (7,308 units at $55.23), increasing direct ownership by 35% to 19,923 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Entry into a Material Definitive Agreement8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesVANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded w
- INSIDERChief Legal Officer Difabio Andrea converted options into 7,500 shares and sold $156,702 worth of shares (2,607 units at $60.11) (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERChief Medical Officer Kenney Christopher John sold $166,559 worth of shares (2,771 units at $60.11) and converted options into 7,500 shares (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERPRESIDENT & CEO Mortimer Ian exercised 290,000 shares at a strike of $6.28 and sold $16,966,500 worth of shares (281,269 units at $60.32), increasing direct ownership by 146% to 14,731 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECSEC Form FWP filed by Xenon Pharmaceuticals Inc.FWP - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- PRXenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public OfferingVANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a
- SECSEC Form 424B5 filed by Xenon Pharmaceuticals Inc.424B5 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon Pharmaceuticals Announces Proposed Public OfferingVANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offer
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00
- PRXenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information: Date:Monday, March 9, 2026 Time:8:00 am ET (5:00 am PT) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:78
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form 424B5 filed by Xenon Pharmaceuticals Inc.424B5 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form 10-K filed by Xenon Pharmaceuticals Inc.10-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)